Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The approval comes after a systematic review of published literature
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
